Search

Register now and experience an awesome adventure into the world of Science, Technology, Engineering and Mathematics this August!

Embark on a linguistic journey with KalyaKoorl’s tailor-made Noongar Language Programs.

Research

Sepsis, for children and their parents, is a life-altering illness with far-reaching psychosocial and physical impacts. We aimed to explore the needs of such patients and their parents after hospital admission for sepsis to inform the development of a Western Australian postsepsis care service.  

Research

Nirsevimab is a long-acting monoclonal antibody used to prevent respiratory syncytial virus (RSV) infection in infants and high-risk children. During the 2024 RSV season in Western Australia, 21 922 doses were administered to infants entering their first season and 1221 doses to at-risk children. In this context, the selection and spread of escape variants are a potential concern. This study aimed to investigate nirsevimab binding site mutations using clinical and wastewater data.

Join us for stories, imagination and connection in the Discovery Centre

Researchers from The Kids Research Institute Australia would like to understand more about respiratory syncytial virus (RSV) and how we can provide the best protection for kids.

Vaccine Trials Group with Sir Charles Gairdner Hospital is conducting a trial of a vaccine against Clostridium difficile infection (CDI) in at-risk individuals.

Researchers at The Kids Research Institute Australia are studying a new pneumococcal vaccine designed to provide a broader protection for 21 serotypes of the bacteria S. pneumoniae – 8 more serotypes than the current vaccine given to new babies.

Highlights from the VTG Laboratory in 2025

RSV Update